2[2]Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies uses first-line agents: a systemic review and meta-analysis[J] .JAMA, 1997, 277(9):739 - 745.
3[3]Messerli FH, Grossmen E, Gooldbout U.Are β- blocker efficacious as first-line therapy for hypertension in the elderly [J] ?JAMA, 1998,279( 11 ): 1903 - 1907.
4[6]Tuomilehto J , Rastenyte D, Birkenhager WH, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension in Europe Trial Investigators[J]. N Engl J Med, 1999, 340(9): 677-684.
5[7]Estaeio RO, Jeffers BW, Hiatl WR, et al. The effect of misoldipine compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension [J] .N Engl J Med , 1998, 38(8): 645 -652.
6[8]Liu L, wang JG,Gong Let al. For the systolic Hypertension in China (Syst-China). Collaborative Group Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension[J]. J Hypertension, 1998, 16 ( 12 ): 1823- 1829.
7[9]Brophy JM, Deslauriers G, Rouleaul JL.long-term prognosis of patients presenting to the emergency room with presenting to the emergency room which decompensated congestive heart failure[J] .Can J cardiol, 1994, 10(9): 543 - 547.
8[14]Dahlof B Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE) :A randomized trial against atenolol[J]. Lancet , 2002,359(9311 ): 995 - 1003.
